CGM Use in Adults With Type 2 Diabetes on Basal Insulin

Condition(s) studied

Investigational drug(s) / intervention(s)

FreeStyle Libre 3 Continuous Glucose Monitoring System.: Subjects will be randomised to use the FreeStyle Libre 3 system

Self monitoring of blood glucose: Subjects will be randomised to continue with their current glucose monitoring system

Study summary

A prospective multi-centre, open-label, two arm, parallel design, superiority, pragmatic, randomised controlled trial, over an 8-month period. The purpose of this study is to determine whether continuous glucose monitoring using FreeStyle Libre 3 will improve HbA1c compared to SMBG over 16 weeks in adults with sub-optimally controlled (HbA1c 7.5-11%) Type 2 diabetes on basal therapy.

Following completion of the 8-month period for all participants, an optional non-interventional follow-up period will assess glycaemic control and treatment patterns over 24 months.

Eligibility

Primary outcome measure(s)

• HbA1c — 16 weeks
  Difference between treatment groups in mean change from baseline in HbA1c.

Trial sites (25)

Other trials for the same condition